Activation of Retinoid X Receptor increases dopamine cell survival in models for Parkinson's disease

Stina Friling, Maria Bergsland and Susanna Kjellander*

Address: The Ludwig Institute for Cancer Research, Stockholm Branch, Box 240, S-171 77 Stockholm
Email: Stina Friling - stina.friling@vgregion.se; Maria Bergsland - maria.bergsland@licr.ki.se; Susanna Kjellander* - kjellander@sbu.se
* Corresponding author

Abstract

Background: Parkinson's disease (PD) is caused by degeneration of dopamine (DA) neurons in the ventral midbrain (vMB) and results in severely disturbed regulation of movement. The disease inflicts considerable suffering for the affected and their families. Today, the opportunities for pharmacological treatment are meager and new technologies are needed. Previous studies have indicated that activation of the nuclear receptor Retinoid X Receptor (RXR) provides trophic support for DA neurons. Detailed investigations of these neurotrophic effects have been hampered by the lack of readily available DA neurons in vitro. The aim of this study was to further describe the potential neurotrophic actions of RXR ligands and, for this and future purposes, develop a suitable in vitro-platform using mouse embryonic stem cells (mESCs).

Results: We studied the potential neurotrophic effects of the RXR ligand LG100268 (LG268) and the RXR-Nurr1 ligand XCT0139508 (XCT) in neuronal cultures derived from rat primary vMB and mESCs. RXR ligands protect DA neurons from stress, such as that induced by the PD-modeling toxin 6-hydroxy dopamine (6-OHDA) and hypoxia, but not from stress induced by oxidative hydrogen peroxide (H₂O₂) or the excitotoxic agent kainic acid (KA). The neurotrophic effect is selective for DA neurons. DA neurons from rat primary vMB and mESCs behaved similarly, but the mESC-derived cultures contained a much higher fraction of DA cells and thus provided more accessible experimental conditions.

Conclusions: RXR ligands rescue DA neurons from degeneration caused by the PD simulating 6-OHDA as well as hypoxia. Thus, RXR is a novel promising target for PD research. mESC-derived DA cells provide a valid and accessible in vitro-platform for studying PD inducing toxins and potential trophic agents.

Background
PD is caused by progressive degeneration of dopaminergic neurons in the substantia nigra of the vMB [1-3]. The resulting lack of the neurotransmitter DA leads to decreased signaling within the nigro-striatal pathway and produces disturbed regulation of movement with tremor, bradykinesia and rigidity [4]. As of today, there is no cure for PD.

Nuclear hormone receptors (NRs) are emerging as interesting factors in PD research. Most NRs are regulated by small, lipophilic ligands that easily enter the cell nucleus to control transcription. RXR (NR2B1-3) is activated by
the synthetic ligand LG268 [5]. Interestingly, this activation has been shown to rescue DA neurons from degeneration in survival assays based on primary cultures [6]. Increased survival was dependent on activation of the heterodimer between RXR and the orphan NR, Nurr1 (NR4A2), as substantiated by several findings. Survival was selective for Nurr1-expressing neurons in vMB as well as cortex and the effects were abolished in cortical cultures from Nurr1 knock-out mice. Furthermore, the ligand XCT, which is selective for the Nurr1-RXR heterodimer, also increased vMB DA neuron survival. Nurr1 is essential for vMB DA neuron development [7], regulates genes essential for DA synthesis and storage [8-10], and has been indicated to have a role in neuroprotection of mature DA cells in several studies [11,12]. Indeed, human Nurr1-mutations have been associated with familial PD [13], providing clinically relevant evidence for such a role.

The origin of DA cell degeneration in PD is largely unknown, but it is suggested to be caused by agents causing oxidative damage and energy depletion in the brain [14-16]. The hydroxylated DA analogue 6-OHDA is commonly used to model nigral degeneration in experimental animals as well as in vitro, where it causes DA cell death and neurotransmitter depletion [17]. In vitro, its uptake is selective for DA cells through the DA transporter, and when inside the neuron, 6-OHDA produces oxidative stress [18,19] as well as mitochondrial inhibition [20]. Several other stressors can also be used to induce neurodegeneration and stress, for example hypoxic environments [21], the oxidative agent H$_2$O$_2$ [22,23], and the excitotoxic glutamate analogue KA [24-26].

Primary neuronal cultures provide data of high biological relevance. However, their use is diminished by low yields and high technical demands. Recently, we developed a platform for in vitro studies using DA cells derived from mESCs. Overexpression of the homeobox domain containing transcription factor Lmx1a under the control of the neuroprogenitor specific Nestin enhancer (NesE) induces formation of high numbers of bona fide vMB DA neurons in culture [27]. These neurons express all relevant neurotransmitters, show proper electrophysiological characteristics as well as physiological levels of DA and metabolites. Moreover, they survive and regenerate when grafted into 6-OHDA lesioned rat brains [28].

Here we have used DA neurons derived from primary vMB cultures as well as mESCs to further establish the neurotrophic role of RXR activity. We can show that RXR ligands protect DA neurons from stress caused by 6-OHDA and hypoxia, but not from KA and H$_2$O$_2$. The protective effects are only seen in Nurr1-expressing DA cells. To conclude, RXR ligands and mESC-derived DA cells represent promising platforms in the search for novel PD therapies.

Results and discussion

Since primary neurons are retrieved directly from developing brain tissue, artifacts are small, assuring data of high biological relevance. Primary neuronal cultures were prepared from rat E14.5 vMB. The initial extensive neurodegeneration declined significantly within approximately 24 hours of plating and after three days in vitro (DIV) the cell death was negligible, whereby the cultures could be maintained for weeks (also see [29]). After three DIV, neurons have clearly visible neurites and a mature neuronal morphology. Approximately 2-3% of the neurons in the vMB cultures was dopaminergic and could be identified by immunostaining against the rate-limiting enzyme in DA synthesis, tyrosine hydroxylase (TH). To investigate the specificity of the RXR effects on neuronal survival, several stressors were used.

RXR ligands rescue primary vMB DA neurons from 6-OHDA-induced degeneration

To study whether the neurotrophic activities of the RXR ligands were general or rather selective for specific cellular threats, none of the ligands alone had any effect on cell survival. RXR is ubiquitously expressed and it heterodimerizes with several NR subtypes. However, RXR-ligand dependent neurotrophic effects have been shown to be mediated through Nurr1 [6]. Here, the positive ligand effects after 6-OHDA exposure were only seen for the Nurr1 expressing DA neurons, whereas no neuronal rescue could be detected for the general neuronal population in the culture, as determined by scoring TuJ1-positive cells (Figure 1D). To further relate the trophic effects to Nurr1, we used the RXR ligand XCT, which is selective for the Nurr1-RXR heterodimer in the dose applied (1 μM, see [6]). Indeed, XCT rescued vMB DA neurons to 103% of control (p < 0.001, 6-OHDA vs. XCT + 6-OHDA) (Figure 1C). RXR is ubiquitously expressed and it heterodimerizes with several NR subtypes. However, RXR-ligand dependent neurotrophic effects have been shown to be mediated through Nurr1 [6]. Here, the positive ligand effects after 6-OHDA exposure were only seen for the Nurr1 expressing DA neurons, whereas no neuronal rescue could be detected for the general neuronal population in the culture, as determined by scoring TuJ1-positive cells (Figure 1D). To further relate the trophic effects to Nurr1, we used the RXR ligand XCT, which is selective for the Nurr1-RXR heterodimer in the dose applied (1 μM, see [6]). Indeed, XCT rescued vMB DA neurons to 103% of control (p < 0.001, 6-OHDA vs. XCT + 6-OHDA) (Figure 1C). Without exposure to toxic stress, none of the ligands alone had any effect on cell number at three to five DIV (data not shown).

RXR ligand rescues primary vMB DA neurons from degeneration caused by hypoxia, but not from KA and H$_2$O$_2$

To study whether the neurotrophic activities of the RXR ligands were general or rather selective for specific cellular conditions, we exposed primary vMB cultures to hypoxia, KA and H$_2$O$_2$. The RXR ligand rescues primary vMB DA neurons from degeneration caused by hypoxia, but not from KA and H$_2$O$_2$.
challenges, we studied their effects on several types of stressors and toxins. Primary vMB DA neurons of three to five DIV were stressed by hypoxic culture conditions (0-1% O₂, 5% CO₂). Ligands were added three hours prior to the hypoxic insult and kept throughout the experiment. Cells were fixed, stained and scored after different time intervals. In control culture conditions there is no decrease in the number of DA cells over time. However, hypoxia induced a time dependent decrease in DA cells (ANOVA, p < 0.001, F 55.2) (Figure 2A). Simultaneous exposure of LG268 during 24 and 36 hours in hypoxic conditions partly rescued the DA cells, giving a 30% (p = ns) and 40% (p < 0.05) increase, respectively, compared to the untreated cells (Figure 2B). Further, the excitotoxic glutamate analogue KA and the oxidative agent H₂O₂ were applied to primary vMB neurons of three to five DIV. KA as well as H₂O₂ exposure resulted in dose dependent degeneration of the DA neurons (ANOVA, p < 0.001, F 277.9) (H₂O₂, ANOVA, p < 0.001, F 79.4) (Figures 2C and 2D). However, addition of the RXR ligands LG268 or XCT provided no neuronal rescue at any of the doses tested. This implies that the ligands are acting on specific cell death mechanisms, induced by 6-OHDA and hypoxia, but not on the calcium dependent excitotoxicity caused by KA or the pure oxidative stressor H₂O₂.

**RXR ligands rescue mESC-derived DA neurons from 6-OHDA-induced degeneration**

We further used mESC-derived DA cells as platforms for our evaluation of RXR ligands. These cells represent great...
progress for in vitro studies, since they provide a very high number of the correct cell type and homogeneous cultures. Stable NesE-Lmx1a mESCs (Lmx1a cells) were induced for neuronal differentiation as monolayer cultures in medium supplemented with the DA instructive cues Sonic Hedgehog (Shh) and Fibroblast growth factor (FGF) 8 [28]. After 18 days of differentiation, cells have a mature phenotype with long extended neuritis and expression of relevant DA cell proteins including TH (Figure 3, see also [28]). Cells were given RXR ligands for three hours and were then exposed to 6-OHDA for another three hours. Subsequently, media was changed and fresh ligands were added. Cultures were kept for additional 48 hours before fixation, staining and scoring. 6-OHDA produced a dose dependent toxicity, with reduced number of TH-positive cells by 52% and 98% compared to untreated cultures, respectively (black bars). LG268 provided no rescue (grey bars). RXR ligand rescues primary DA neurons from hypoxia, but not from KA or H2O2-induced toxicity Figure 2. A) Hypoxia induced a time dependent decrease in the number of primary DA cells, giving 18%, 42% and 49% reduction after 7, 24 and 36 hours in 0-1% O2, respectively. B) LG268 treatment (grey bars) during hypoxic conditions partly rescued the DA cells, giving a 30% and 40% increase in TH+ cells compared to the cultures without added ligand after 24 and 36 hours, respectively. C) KA exposure at 100 and 500 μM reduced the number of primary DA cells by 52% and 98% compared to untreated cultures, respectively (black bars). LG268 provided no rescue (grey bars). D) H2O2 exposure at 80 and 110 μM gave 70 and 83% neurodegeneration, respectively (black bars). This could not be restored by addition of LG268 (grey bars). Stars (*) refer to differences between control-group (N2) and experimental-group, whereas values above brackets refer to differences between different experimental-groups. ns denotes non-significant, * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001 according to Tukey’s multiple comparison test.
RXR ligands selectively rescue mESC-derived DA neurons from 6-OHDA toxicity. A) 6-OHDA produced a dose-dependent toxicity in Lmx1a overexpressing mESC-derived DA cells. Three hours exposure of 150, 250 and 500 μM 6-OHDA reduced the number of DA cells by 33%, 55% and 82%, respectively. B) At 250 μM 6-OHDA, addition of LG268 and XCT completely rescued the DA neurons, from 55% reduction to 100% and 116% of control, respectively. C) Colony of mESC-derived DA cells stained red with Cy3-conjugated anti-TH antibody. 6-OHDA reduced the number of TH-positive cell bodies and remaining cells have degenerate morphology. Simultaneous treatment with LG268 rescued the TH-positive cells from degeneration. Stars (*) refer to differences between control-group (N2B27) and experimental-group, whereas values above brackets refer to differences between different experimental-groups. * denotes p < 0.05, ** denotes p < 0.01 and *** denotes p < 0.001 according to Tukey's multiple comparison test.

PD inflicts considerable suffering for the affected and their families, and it constitutes a great cost for the society. Today, the opportunities for pharmacological treatment are meager and mainly consist of substitution with the DA precursor Levodopa. However its medical potential decreases severely over time [30]. The development of neuroprotective or neuroregenerative therapies would provide great benefits. As such, glial cell line-derived neurotrophic factor (GDNF) has been tested in several clinical trials against PD [31-35]. Unfortunately, lack of efficacy and potential hazardous side effects has lessened the initial enthusiasm, and future development of GDNF-based treatments seems unlikely.
drug therapies seems uncertain. Thus, there is a high need for alternative strategies to treat PD.

NR ligands are small and lipophilic, and they easily pass the blood-brain-barrier, providing excellent targets for the pharmaceutical industry. Indeed, the characterization of novel NR-mediated signaling pathways during the last decade has resulted in development of novel drugs used in the treatment of metabolic disease and cancer. Specifically, RXR ligands have limited toxicity in humans [36] and selective RXR ligands would minimize the risk of adverse effects. Our findings that RXR activity leads to neuroprotection [6] provide novel possible approaches to PD research. The neuroprotective effect is mediated, at least partly, by the Nurr1-RXR dimer. Here, we further show that RXR ligands provide neurotrophic support after stress induced by the PD modeling toxin 6-OHDA. The effects are selective for the Nurr1-expressing DA cells and do not affect total neuronal number in the cultures. Interestingly, neuroprotective effects are also seen after hypoxia-induced neurodegeneration. No protective effects are seen after excitotoxic or pure oxidative stress induced by KA and H2O2, respectively. Thus, the effects of ligand activation is not generally neuroprotective, but rather likely to affect individual cell death pathways.

Conclusions
Ligands activating RXR and the RXR-Nurr1 heterodimer selectively protect DA neurons from stress induced by the PD-modeling toxin 6-OHDA and hypoxia. Thus, the regulation of RXR activity holds promises to contribute to a novel, alternative strategy in PD treatment. Furthermore, mESC-derived cultures offer accessible platforms of DA neurons and may provide novel means to conduct valid in vitro-based PD research.

Methods
Primary vMB Cultures
All experiments were performed in accordance with guidelines from the Swedish National Board for Laboratory Animals. Primary vMB cultures were obtained as previously described [6]. Briefly, vMB from rat embryos at stage E14.5 were dissected, mechanically dissociated and plated on poly-D-lysine coated 12 or 24 well plates in serum free medium (N2) consisting of a 1:1 mixture of MEM (Gibco, UK) with 15 mM Hepes buffer (Gibco, UK) and Ham's F12 medium (Gibco, UK). The mixture was supplemented with 6 mg/ml glucose, 1 mg/ml bovine serum albumine, 5 μg/ml insulin, 100 μg/ml transferrin, 60 μM putrescine, 20 nM progesterone, 30 nM selenium and 1 mM glutamine (Sigma). Cultures were incubated for three to five DIV before treatment. Cultures were kept in 37 °C, 5% CO2 and 99% humidity unless otherwise stated.

DA cells derived from Lmx1a-expressing mESCs
DA cells were derived from E14.1 mESCs as previously described [27,28]. Briefly, mESCs were propagated in feeder free conditions in DMEM (Invitrogen) supplemented with 2000 U/ml LIF (Chemicon), 9% KSR, 3% FBS, 0.1 mM non-essential amino acids, 1 mM pyruvate (Invitrogen) and 0.1 μM β2-mercaptoethanol (Sigma). For generation of stable ESC lines, 2 × 10^5 cells were nucleofected with 7 μg linearized NesE-mLmx1a-PGK-neo vector according to protocol (mouse ESC nucleofector kit, Amaxa biosystems Gmbh, Koeln, Germany), selected with G418, replated on gelatinized dishes and induced to differentiate in N2B27 differentiation medium [37] supplemented with 20 ng/ml bFGF, 100 ng/ml FGF8 and 70 nM Shh. Cells were incubated for 18 days before treatment. Cultures were kept in 37 °C, 5% CO2 and 99% humidity throughout all experiments.

Ligands and stressors
Experiments were performed in triplicates. The ligands (stock solutions in DMSO; LG268 and XCT, kindly provided by Dr. Mark Leibowitz at Ligand Pharmaceuticals and Dr. Peter Ordentlich at X-ceptor pharmaceuticals, respectively), were diluted to working dilutions in culture medium and added to the cultures for two to three hours prior to neurodegenerative stressors. Final concentrations were 0.1 and 1 μM for LG268 and XCT, respectively. The DA analogue 6-OHDA was given to the vMB primary neuron cultures at 5-15 μM for 20 minutes before medium and ligand replacement. Hypoxic stress was induced by placing cultures in a modular incubator chamber (Billups-Rothenberg Inc., Del Mar, CA) at 37 °C filled with 5% CO2 and 0-1% O2 (balanced with N2) from one to 36 hours. The excitotoxic glutamate analogue KA and the oxidative agent H2O2, were added over night, in the range of 100 to 500 μM and 80 to 110 μM, respectively. To stress mESC-derived DA cells, 150 to 500 μM 6-OHDA in 0.1% ascorbic acid were added three hours before medium and ligand exchange. The cultures were left for another 36 hours in the incubator.

Immunocytochemistry
Paraformaldehyde fixed cultures were incubated overnight with TH (1:1000, Pel-Freez, Arkansas), TuJ1 (1:1000, Babco) antiserum in PBS containing 5% fetal calf serum and 0.3% triton X-100. Following rinses, cultures were incubated with FITC- and Cy3 conjugated secondary antibodies (Jackson, ImmunoResearch, West Grove, PA) for direct detection or with biotinylated secondary antibodies followed by detection of immuno-staining using the ABC immunoperoxidase kit from Vector (Buringame, CA).
Microscopical analysis and image collection
Analysis, imaging and cell counting were performed on Eclipse E1000M and Eclipse TE300 microscopes (both Nikon) coupled to the Spot2 camera (Diagnostic Instruments, Sterling Heights, MI). Scoring was performed by cell counting, and counts were made blind to avoid observation bias. Statistical analyses were performed by one-way analysis of variance (ANOVA) followed by Tukey's multiple comparison test when appropriate.

Abbreviations
6-OHDA: 6-hydroxy dopamine; ANOVA: one-way analysis of variance; DA: dopamine; DIV: days in vitro; FGF: Fibroblast growth factor; GDNF: glial cell line-derived neurotrophic factor; H₂O₂: hydrogen peroxide; KA: Kainic acid; LG268: LG100268; mESCs: mouse embryonic stem cells; NesE: Nestin Enhancer; ns: non-significant NRs; Nuclear hormone receptors; PD: Parkinson Disease; RXR: Retinoid × receptor; Shh: Sonic Hedgehog; TH: tyrosine

Authors' contributions
SF constructed the stable Lmx1a mESC line, performed dopamine synthesis and storage in MN9D dopamine cells. Exp Cell Res 2003, 288:324-334.
Le W, Conneely OM, He Y, Jankovic J, Appel SH: Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem 1999, 73:2218-2221.

Acknowledgements
We thank Prof. Thomas Perlmann at LICR for facilities and valuable scientific discussions. We also thank Dr. Mark Leibowitz at Ligand Pharmaceuticals and Dr. Peter Ordentlich at X-ceptor Pharmaceuticals for providing the RXR ligands used in this study. This work was funded by The Swedish Research Council support to Strategic Center for Developmental Biology and Regenerative Medicine (DBRM).

References
1. Selby G: The long-term prognosis of Parkinson's disease. The Graeme Robertson Memorial Lecture 1983. Clin Exp Neurol 1983, 20:1-25. 1984
2. Spillantini MG, Goedert M: The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000, 920:16-27.
3. Shstry BS: Parkinson disease: etiology, pathogenesis and future of gene therapy. Neurosci Res 2001, 41:5-12.
4. Gerfen CR, Wilson CJ: The basal ganglia. In Handbook of chemical neuroanatomy Volume 12. Edited by: Swanson LW, Bjorklund A, Hokfelt T. Amsterdam: Elsevier; 1996:371-468. [Björklund A, Hokfelt T (Series Editor): Integrated systems of the CNS, part III]
5. Boehm M F, Zhang L, Zhi L, McClung M R, Berger E, Wagener M, Mais D E, Suto C M, Davies P JA, Heyman R A, Nadzan A M: Design and synthesis of potent retinoid × receptor selective ligands that induce apoptosis in leukemia cells. J Med Chem 1995, 38:146-3155.
6. Wallen-Mackenzie Å, Mata de Urquiza A, Petersson S, Rodriguez FJ, Friling S, Wagner J, Ordentlich P, Lengqvist J, Heyman RA, Arenas E, Perlmann T: Nurr1-RXR heterodimers mediate RXR ligand-induced signaling in neuronal cells. Genes and Development 2003, 17(24):3036-47.
7. Zetterström RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T: Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997, 276:248-252.
8. Iwakawi T, Kohno K, Kobayashi K: Identification of a potential nurr1 response element that activates the tyrosine hydroxylase gene promoter in cultured cells. Biochem Biophys Res Commun 2000, 274:590-595.
9. Sacchetti P, Mitchell D R, Granneman JG, Bannor MJ: Nurr1 enhances transcription of the human dopamine transporter gene through a novel mechanism. J Neurochem 2001, 76:1565-1572.
10. Hermanson E, Joseph B, Castro D, Lindqvist E, Aarnisalo P, Wallen A, Benat G, Hengerer B, Olson L, Perlmann T: Nurr1 regulates dopamine synthesis and storage in MN9D dopamine cells. Exp Cell Res 2003, 288:324-334.
11. Le W, Conneely OM, He Y, Jankovic J, Appel SH: Reduced Nurr1 expression increases the vulnerability of mesencephalic dopamine neurons to MPTP-induced injury. J Neurochem 1999, 73:2218-2221.
12. Eells JB, Yeung SK, Nikodem VM: Dopamine neurons heterozygous for the Nurr1-null allele have reduced survival in vitro. Neurosci Res Commun 2002, 30:173-183.
13. Le WD, Xu P, Jankovic J, Jhang H, Appel SH, Smith RG, Vassilakis DK: Mutations in NR4A2 associated with familial Parkinson disease. Nat Genet 2003, 3:385-389.
14. Ritz B, Yu F: Parkinson's disease mortality and pesticide exposure in California 1984-1994. Int J Epidemiol 2000, 29:323-329.
15. Beal MF: Experimental models of Parkinson's disease. Nat Rev Neurosci 2001, 2:325-334.
16. Langston JW: Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol 1999, 46:45-52.
17. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna T. Amsterdam: Elsevier; 1996:371-468. [Björklund A, Hökfelt T (Series Editor): Integrated systems of the CNS, part III]
18. Chang BS: Dopamine neurons heterozygous for the Nurr1-null allele have reduced survival in vitro. Neurosci Res Commun 2002, 30:173-183.
19. Choi WS, Yoon SY, Oh TH, Choi EJ, O'Malley KL, Oh YJ: Two distinct mechanisms are involved in 6-hydroxydopamine- and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J Neurosci Res 1999, 57:86-94.
20. Kumar R, Agarwal AK, Seth PK: Free radical-generated neurotoxicity of 6-hydroxydopamine. J Neurochem 1995, 64:1703-1707.
21. Glinka Y, Tipton KF, Youdim MB: Nature of inhibition of mitochondrial respiratory complex I by 6-Hydroxydopamine. J Neurochem 1996, 66:2004-2010.
22. Huddard GG, Jiang C: O2 deprivation in the central nervous system: on mechanisms of neuronal response, differential sensitivity and injury. Prog Neurobiol 1993, 40:277-318.
23. Chinopoulos C, Adam-Vizi V: Mitochondria deficient in complex I activity are depolarized by hydrogen peroxide in nerve terminals: relevance to Parkinson's disease. J Neurochem 2001, 76:302-306.
24. Trettter L, Sipos I, Adam-Vizi V: Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochem Res 2004, 29:569-577.
25. Sun AY, Cheng y, Bu Q, Oldfield F: The bio-chemical mechanisms of the excitotoxicity ofkainic acid. Free radical formation. Mol Chem Neuropathol 1990, 17:61-63.
26. Cheng Y, Sun A: Oxidative mechanisms involved in kainate-induced cytotoxicity of cortical neurons. Neurochem Res 1994, 19:1557-1564.
27. Wang Q, Yu S, Simonyi A, Sun G, Sun A: Kainic Acid-Mediated Excitotoxicity as a Model for Neurodegeneration. Molecular Neurobiology 2005, 31:3-16.
28. Andersson E, Tryggvason U, Deng Q, Friling S, Alekseenko Z, Robert B, Perlmann T, Ericson J: Identification of intrinsic determinants of midbrain dopamine neurons. Cell 2006, 124:393-405.
29. Friling S, Andersson E, Thompson L, Jönsson M, Hebsgaard J, Nanou E, Alekseenko Z, Marklund U, Perlmann T, Ericson J: Efficient Production of Mesencephalic Dopamine Neurons by Lmx1a Expression in Embryonic Stem Cells. Proc Natl Acad Sci USA 2009, 106:7613-8.
30. Branton RL, Clarke DJ: Apoptosis in primary cultures of E14 rat ventral mesencephala: time course of dopaminergic cell
death and implications for neural transplantation. Exp Neurol 1999, 160:88-98.
30. Dunnett SB, Bjorklund A: Prospects for new restorative and neuroprotective treatments in Parkinson’s disease. Nature 1999, 399:A32-39.
31. Nutt JG, Burchiel KJ, Cornella CL, Jankovic J, Lang AE, Laws ER Jr, Lozano AM, Penn RD, Simpson RK Jr, Stacy M, Wooten GF. Randomized, double-blind trial of glial cell line-derived neurotrophic factor (GDNF) in PD. Neurology 2003, 60:69-73.
32. Gill SS, Patel NK, Hotton GR, O’Sullivan K, McCarter R, Bunnage M, Brooks DJ, Svendsen CN, Heywood P. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat Med 2003, 9:589-595.
33. Slevin JT, Gerhardt GA, Smith CD, Gash DM, Kryscio R, Young B: Improvement of bilateral motor functions in patients with Parkinson disease through the unilateral intraputaminal infusion of glial cell line-derived neurotrophic factor. J Neurosurg 2005, 102:216-222.
34. Lang AE, Gill S, Patel NK, Lozano A, Nutt JG, Penn R, Brooks DJ, Hotton G, Moro E, Heywood P, Brodsky MA, Burchiel K, Kelly P, Dalvi A, Scott B, Stacy M, Turner D, Wooten VG, Elias WJ, Laws ER, Dha-awan V, Stoessl AJ, Matcham J, Coffey RJ, Traub M: Randomized controlled trial of intraputaminal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006, 59:459-466.
35. Sherer TB, Fiske BK, Svendsen CN, Lang AE, Langston JW: Crossroads in GDNF therapy for Parkinson’s disease. Mov Disord 2006, 21:136-141.
36. Hurst RE: Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs 2000, 1:514-523.
37. Ying QL, Smith AG: Defined conditions for neural commitment and differentiation. Methods Enzymol 2003, 365:327-341.